Extracellular vesicles produced by a large-scale protocol are therapeutically effective in preclinical model of Parkinson’s disease
Stem Cells Translational Medicine · 27.04.2026 · 15 (5)
DOI: 10.1093/stcltm/szag024 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Stem Cells Translational Medicine, online erschienen am 29.04.2026. Verfasst von Agnė Pociūtė und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stem Cell Biology, State Research Institute Centre for Innovative Medicine, Vilnius, LT-01102, Lithuania. Hauptthemen laut MEDLINE: Extracellular Vesicles, Parkinson Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union's Recovery and Resilience Mechanism, European Union’s Recovery and Resilience Mechanism.
Abstract (Originalsprache)
Background
Therapeutic applications require large amounts of extracellular vesicles (EVs) that cannot be obtained by standard laboratory protocols. Since culturing parameters and isolation methods can significantly affect the molecular composition and therapeutic efficacy of EVs, the development of a new scale-up protocol should be followed by the molecular fingerprinting and validation of therapeutic potential in vivo.
Methods
We developed a new scale-up protocol based on microcarrier culture (3D) of immortalized human dental pulp stem cells in a spinning bioreactor and subsequent isolation of EVs by 2-step tangential flow filtration (TFF) and size exclusion chromatography (SEC).
Results
A new scale-up protocol increased EV yields by 463-fold. When compared with ultracentrifugation (UC), isolation using TFF/SEC substantially reduced the complexity of proteomic cargo, whereas culture conditions (2D vs. 3D) affected miRNA, but not mRNA and proteomic content of the EVs. We next compared the therapeutic efficacy of both EV products in 6-hydroxydopamine rat model of Parkinson’s disease (PD). The same amounts of EVs derived from standard 2D cultures by UC and a new large-scale protocol were intranasally administered to PD rats, where they similarly improved gait and cognitive functions, preserved nigrostriatal tyrosine hydroxylase density and suppressed neuroinflammation. Notably, both EV preparations were enriched in proteins and miRNAs associated with anti-oxidative and anti-inflammatory responses.
Conclusion
Our protocol allows large-scale production of EVs that are therapeutically effective in the pre–clinical model of PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Stem Cell Biology, State Research Institute Centre for Innovative Medicine, Vilnius, LT-01102, Lithuania.
- Faculty of Medicine and Life Sciences, University of Latvia, Riga, LV-1004, Latvia.
- Latvian Biomedical Research and Study Center, Riga, LV-1067, Latvia.
- TAmiRNA GmbH, Vienna, 1110, Austria.
ORCID-Profile: Agnė Pociūtė, Matthias Hackl
Förderung
- European Union's Recovery and Resilience Mechanism
- European Union’s Recovery and Resilience Mechanism
Zitieren
APA
Pociūtė, A., Tunaitis, V., Žebrauskas, A., Pilipenko, V., Jansone, B., Narbute, K., Pultar, M., Hackl, M., & Pivoriūnas, A. (2026). Extracellular vesicles produced by a large-scale protocol are therapeutically effective in preclinical model of Parkinson’s disease. Stem Cells Translational Medicine, 15(5). https://doi.org/10.1093/stcltm/szag024
Vancouver
Pociūtė A, Tunaitis V, Žebrauskas A, Pilipenko V, Jansone B, Narbute K, et al. Extracellular vesicles produced by a large-scale protocol are therapeutically effective in preclinical model of Parkinson’s disease. Stem Cells Translational Medicine. 2026;15(5). doi:10.1093/stcltm/szag024
BibTeX
@article{Pocit2026,
author = {Pociūtė, Agnė and Tunaitis, Virginijus and Žebrauskas, Arūnas and Pilipenko, Vladimirs and Jansone, Baiba and Narbute, Karina and Pultar, Marianne and Hackl, Matthias and Pivoriūnas, Augustas},
title = {Extracellular vesicles produced by a large-scale protocol are therapeutically effective in preclinical model of Parkinson’s disease},
journal = {Stem Cells Translational Medicine},
year = {2026},
volume = {15},
number = {5},
doi = {10.1093/stcltm/szag024}
}
EUVIMED